# Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct06407310/  
OnCo record `nct06407310` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab, carboplatin and paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Tel Aviv Medical Center, not yet recruiting.

## Summary

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer is a phase 2, interventional study registered as NCT06407310 by Tel Aviv Medical Center, with a registry enrolment figure of 25 participants, started 2024-07-01 and due to reach its primary completion in 2027-04-01. Interventions recorded: Pembrolizumab; Carboplatin; Paclitaxel. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Male/female participants who are at least 18 years of age on the day of signing informed consent with a histologically confirmed diagnosis of stage I or II TNBC". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06407310
- Phase: 2
- Setting: Phase II Open-label, Single-arm Trial of Neoadjuvant Pembrolizumab With Carboplatin and Paclitaxel in Triple-negative Breast Cancer
- Sponsor: Tel Aviv Medical Center
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT06407310: https://clinicaltrials.gov/study/NCT06407310

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06407310.json